Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Macerata – page 3

31 clinical trials in Macerata, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Macerata at a glance
31
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

31 trials in Macerata

Open in trial search

Breast cancer+3

Not recruiting

Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Bladder cancer

Not recruiting

Study Comparing TAR-200 and Chemotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer After BCG Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mitomycin
  • Sponsor:Janssen Cilag International

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Study of Pembrolizumab and Chemotherapy for Patients with Triple Negative Breast Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Bladder cancer

Not recruiting

Study of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Macerata

What the registry says about research in the country

01 Breast Cancer Research

Extensive clinical trials focusing on triple-negative breast cancer and hormone receptor-positive breast cancer treatments, evaluating innovative therapeutic approaches including immunotherapy combinations and targeted therapies.

  • Advanced treatment sequencing studies
  • Novel drug combinations
  • Hormone therapy optimization

Research emphasizes personalized treatment strategies for different breast cancer subtypes.

02 Urological Oncology

Groundbreaking research in bladder cancer and prostate cancer, investigating new immunotherapy approaches and targeted treatments for both early-stage and advanced disease.

  • Non-muscle invasive bladder cancer therapies
  • Advanced prostate cancer treatments
  • Combination therapy approaches

Studies focus on improving patient outcomes through innovative treatment combinations.

03 Advanced Cancer Therapies

Investigating cutting-edge treatments for metastatic cancers, including studies on renal cell carcinoma and various other advanced malignancies.

  • Targeted therapy development
  • Immunotherapy optimization
  • Personalized treatment approaches

Research aims to improve survival rates and quality of life for patients with advanced disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.